Dynamic strength training improves insulin sensitivity and functional balance between adrenergic alpha 2A and beta pathways in subcutaneous adipose tissue of obese subjects
Language English Country Germany Media print-electronic
Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Epinephrine pharmacology MeSH
- Adrenergic beta-2 Receptor Agonists MeSH
- Adrenergic alpha-2 Receptor Agonists MeSH
- Adrenergic alpha-2 Receptor Antagonists MeSH
- Receptors, Adrenergic, alpha-2 genetics metabolism MeSH
- Receptors, Adrenergic, beta-2 genetics metabolism MeSH
- 3',5'-Cyclic-AMP Phosphodiesterases genetics physiology MeSH
- Exercise physiology MeSH
- Cyclic Nucleotide Phosphodiesterases, Type 3 MeSH
- Adult MeSH
- Phentolamine pharmacology MeSH
- Glycerol analysis blood MeSH
- Glucose Clamp Technique MeSH
- Insulin physiology MeSH
- Insulin Resistance physiology MeSH
- Isoproterenol pharmacology MeSH
- Fatty Acids, Nonesterified blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Lipolysis MeSH
- RNA, Messenger analysis MeSH
- Lipid Metabolism MeSH
- Obesity metabolism physiopathology MeSH
- Subcutaneous Fat, Abdominal chemistry metabolism MeSH
- Sterol Esterase genetics physiology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Epinephrine MeSH
- Adrenergic beta-2 Receptor Agonists MeSH
- Adrenergic alpha-2 Receptor Agonists MeSH
- Adrenergic alpha-2 Receptor Antagonists MeSH
- Receptors, Adrenergic, alpha-2 MeSH
- Receptors, Adrenergic, beta-2 MeSH
- 3',5'-Cyclic-AMP Phosphodiesterases MeSH
- Cyclic Nucleotide Phosphodiesterases, Type 3 MeSH
- Phentolamine MeSH
- Glycerol MeSH
- Insulin MeSH
- Isoproterenol MeSH
- Fatty Acids, Nonesterified MeSH
- RNA, Messenger MeSH
- Sterol Esterase MeSH
AIMS/HYPOTHESIS: The aim of this study was to investigate whether dynamic strength training modifies the control of lipolysis, with particular attention paid to the involvement of the antilipolytic adrenergic alpha 2A receptor (ADRA2A) pathway. METHODS: Twelve obese men (age: 47.4+/-2.8 years; BMI: 32.7+/-0.9) were investigated during a 210-min euglycaemic-hyperinsulinaemic clamp conducted before and after 3 months of dynamic strength training. Before and during the third hour of the clamp, the lipolytic effect of a perfusion of isoproterenol or adrenaline (epinephrine) alone or associated with the ADRA2A antagonist phentolamine was evaluated using the microdialysis method of measuring extracellular glycerol concentration (EGC) in subcutaneous abdominal adipose tissue (SCAAT). In addition, biopsies of SCAAT were carried out before and after training to determine mRNA levels RESULTS: The training increased insulin sensitivity in adipose tissue. The decrease of EGC was more pronounced during the clamp conducted after the training period than during the clamp done in pre-training conditions. Before and after the training, catecholamines induced an increase in EGC, the increase being lower during the clamp on each occasion. The isoproterenol-induced increase in EGC was higher after the training. Adrenaline-induced lipolysis was potentiated by phentolamine after but not before the training. There were no training-induced changes in mRNA levels of key genes of the lipolytic pathway in SCAAT. CONCLUSIONS/INTERPRETATION: In obese subjects, dynamic strength training improves whole-body and adipose tissue insulin responsiveness. It increases responsiveness to the adrenergic beta receptor stimulation of lipolysis and to the antilipolytic action of catecholamines mediated by ADRA2As.
See more in PubMed
J Clin Invest. 1992 May;89(5):1610-7 PubMed
Int J Obes Relat Metab Disord. 1999 Apr;23(4):374-81 PubMed
Horm Metab Res. 1998 Nov;30(11):684-8 PubMed
Metabolism. 1995 Dec;44(12):1513-8 PubMed
Biochem Biophys Res Commun. 1986 Dec 30;141(3):1157-61 PubMed
J Clin Invest. 1993 May;91(5):1997-2003 PubMed
Metabolism. 2005 Jan;54(1):122-31 PubMed
J Biol Chem. 1988 Oct 25;263(30):15553-60 PubMed
Am J Physiol Regul Integr Comp Physiol. 2000 Aug;279(2):R499-504 PubMed
J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10 PubMed
Int J Obes Relat Metab Disord. 1996 Mar;20(3):220-6 PubMed
Am J Clin Nutr. 1992 Jan;55(1 Suppl):228S-236S PubMed
J Clin Endocrinol Metab. 2004 Mar;89(3):1325-31 PubMed
Obes Res. 2003 Feb;11(2):247-56 PubMed
Am J Physiol. 1979 Sep;237(3):E214-23 PubMed
Endocr Rev. 1995 Dec;16(6):716-38 PubMed
Diabetes. 2004 Aug;53(8):1966-71 PubMed
J Clin Endocrinol Metab. 2004 Jan;89(1):135-41 PubMed
Am J Physiol Endocrinol Metab. 2000 Aug;279(2):E376-85 PubMed
Int J Obes Relat Metab Disord. 1995 May;19(5):350-4 PubMed
Nutrition. 2004 Jul-Aug;20(7-8):716-27 PubMed
Anal Biochem. 1989 Jul;180(1):11-6 PubMed
Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E599-607 PubMed
